Previous 10 | Next 10 |
Compugen to Present at Upcoming Industry Conferences PR Newswire HOLON, ISRAEL , June 27, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today ...
Compugen press release (NASDAQ:CGEN): Q1 GAAP EPS of -$0.11 beats by $0.01. Cash balance of $107M affirms focus on capital efficiency with bold execution on Compugen's DNAM-1 axis hypothesis. The company is on track to deliver clinical data from the cohort expansion study of COM701/nivolumab ...
Compugen Reports First Quarter 2022 Results PR Newswire Triple blockade of PVRIG/TIGIT/PD-1 may be required to optimize clinical responses COM701, a unique check point inhibitor, with potential to recruit additional T cells to the TME COM902 has the potential t...
Compugen (NASDAQ:CGEN) is scheduled to announce Q1 earnings results on Monday, May 16th, before market open. The consensus EPS Estimate is -$0.12 Over the last 3 months, EPS estimates have seen 3 upward revisions and 0 downward. For further details see: Compugen Q1 2022 Earnings Preview...
BITF, CGEN, CLSN, CMRX, OTCQB:CVSI, GOED, KALA, LTRY, LUNA, MNMD, NOVN, OEG, PLX, PTE, SOHU, SSYS, SYN, SYRS, TCRT, WEJO, WIX, WRBY For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Monday's open
A group of pharma companies focused on ant-TIGIT class of drugs are trading sharply lower in the pre-market Wednesday after French pharma giant Roche (OTCQX:RHHBY) (OTCQX:RHHBF) announced that a similar treatment failed in a late-stage trial for non-small cell lung cancer (NSCLC). The global ...
Compugen Announces CFO Departure PR Newswire HOLON, Israel , May 10, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that Mr. Ari Krash...
Compugen to Release First Quarter 2022 on Monday, May 16, 2022 PR Newswire HOLON, Israel , May 2, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announc...
Gainers: Randolph Bancorp (RNDB) +24%. NexImmune (NEXI) +8%. Molecular Templates (MTEM) +7%. Hyzon Motors (HYZN) +4%. Compugen (CGEN) +3%. Losers: Aveanna Healthcare Holdings (AVAH) -18%. Marin Software Incorporated (MRIN) -11%. Dave & Buste...
Compugen's Computational Discovery Leverages Single Cell Spatial Transcriptomics to Gain In-Depth Understanding of the Tumor Microenvironment - Combining computational expertise with cutting-edge single cell technology Compugen showed PVRIG at the sites of T cell priming in the ...
News, Short Squeeze, Breakout and More Instantly...
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors PR Newswire FDA clearance triggers a $30 million milestone payment from Gilead Company on track to initiate a Phase 1 trial for COM503, a differentiated antibody approach to harne...
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024 PR Newswire HOLON, Israel , July 23, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target ...
Compugen to Present at Upcoming Antibody Industrial Symposium PR Newswire HOLON, Israel , June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, t...